Drug-eluting medical implants

Handbook of Experimental Pharmacology

Volumn 197, Issue , 2010, Pages 299-341

  Zilberman, Meital ^a   Kraitzer, Amir ^b   Grinberg, Orly ^b   Elsner, Jonathan J ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b NONE

Author keywords

Composite structures; Drug eluting stents; Scaffolds; Stent coatings; Tissue regeneration; Wound dressings

Indexed keywords

'TAXUS'; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTINOMYCIN D; BATIMASTAT; BIOMATERIAL; CHROMIUM; COBALT; CYPHER; DEXAMETHASONE; ETHYLENE VINYL ACETATE COPOLYMER; EVEROLIMUS; GENISTEIN; GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; NANOFILM; PACLITAXEL; PHOSPHORYLCHOLINE; PIMECROLIMUS; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; POVIDONE; RAPAMYCIN; STAINLESS STEEL; TACROLIMUS; TANTALUM; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOTAROLIMUS; TISSUE SCAFFOLD;

BARE METAL STENT; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG COATING; DRUG DIFFUSION; DRUG ELUTING STENT; DRUG HYPERSENSITIVITY; EQUIPMENT DESIGN; HUMAN; IN-STENT RESTENOSIS; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SLOW RELEASE FORMULATION; STENT THROMBOSIS; TISSUE REGENERATION; WOUND DRESSING; ANIMAL; BANDAGE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; INJURY; RESTENOSIS; WOUND HEALING;

ANIMALS; ANTI-BACTERIAL AGENTS; BANDAGES; CORONARY RESTENOSIS; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; HUMANS; POLYMERS; TISSUE SCAFFOLDS; WOUND HEALING; WOUNDS AND INJURIES;

EID: 77953257350     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-00477-3_11     Document Type: Review

References (168)

1. Abizaid A, Lansky AJ, Fitzgerald PJ, Tanajura LF, Feres F, Staico R, Mattos L, Abizaid A, Chaves A, Centemero M, Sousa AG, Sousa JE, Zaugg MJ, Schwartz LB (2007) Percutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimuseluting stent. Am J Cardiol 99:1403-1408
2. Alexis, F., et al., (2004) In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices. J Control Release 98(1):67-74
3. Aoki J, Abizaid AC, Serruys PW, Ong AT, Boersma E, Sousa JE, Bruining N (2005a) Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J Am Coll Cardiol 46:1670-1676
4. Aoki J, Serruys PW, van Beusekom H, Ong AT, McFadden EP, Sianos G, van der Giessen WJ, Regar E, de Feyter PJ, Davis HR, Rowland S, Kutryk MJ (2005b) Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry. J Am Coll Cardiol 45:1574-1579
5. Aoyagi S, Onishi H, Machida Y (2007) Novel chitosan wound dressing loaded with minocycline for the treatment of severe burn wounds. Int J Pharm 330:138-145
6. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini PA (2004) Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. J Am Med Assoc 292:2727-2734
7. Babapulle MN, Eisenberg MJ (2002) Coated stents for the prevention of restenosis: part II. Circulation 106:2859-2866
8. Babensee JE, McIntire LV, Mikos AG (2000) Growth factor delivery for tissue engineering. Pharm Res 17:497-504
9. Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH, Flaherty JD, Ricciardi MJ, Bennett CL, Williams DO (2007) Outcomes and complications associated with off-label and untested use of drug-eluting stents. J Am Med Assoc 297:1992-2000
10. Berg R, Aragon J, Royter V, Shanley JF, Cogert G, Vermani R, Kar S, Eigler N, Litvack F (2007) Pimecrolimus and dual pimecrolimus-paclitaxel eluting stents decrease neointimal proliferation in a porcine model. Catheter Cardiovasc Interv 70:871-879
11. Buchbinder M (2007) Biodegradable stents: BTI approach. Foundation for Cardiovascular Medicine, www.summitmd.com/pdf/pdf/070601-7.pdf
12. Buket Basmanav F, Kose GT, Hasirci V (2008) Sequential growth factor delivery from complexed microspheres for bone tissue engineering. Biomaterials 29:4195-4204
13. Cairns BA, deSerres S, Peterson HD, Meyer AA (1993) Skin replacements. The biotechnological quest for optimal wound closure. Arch Surg 128:1246-1252
14. Chang HI, Lau YC, Yan C, Coombes AG (2008) Controlled release of an antibiotic, gentamicin sulphate, from gravity spun polycaprolactone fibers. J Biomed Mater Res A 84:230-237
15. Chen RR, Mooney DJ (2003) Polymeric growth factor delivery strategies for tissue engineering. Pharm Res 20:1103-1112
16. Chevalier B, Serruys PW, Silber S, Garcia E, Suryapranata H, Hauptmann K, Wijns W, Schuler G, Fath-Ordoubadi F, Worthley S, Thuesen L, Meredith I, Bressers M, Nagai H, Paunovic D (2007) Randomised comparison of NoboriTM, biolimus A9-eluting coronary stent with a Taxus1, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. Euro Intervention 2:426-434
17. Chorny M, Fishbein I, Golomb G (2000) Drug delivery systems for the treatment of restenosis. Crit Rev Ther Drug Carrier Syst 17:249-284
18. Chung LY, Schmidt RJ, Hamlyn PF, Sagar BF, Andrews AM, Turner TD (1994) Biocompatibility of potential wound management products: fungal mycelia as a source of chitin/chitosan and their effect on the proliferation of human F1000 fibroblasts in culture. J Biomed Mater Res 28:463-469
19. Colletta V, Dioguardi D, Di Lonardo A, Maggio G, Torasso F (2003) A trial to assess the efficacy and tolerability of Hyalofill-F in non-healing venous leg ulcers. J Wound Care 12:357-360
20. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME (2003) Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108:788-794
21. Commandeur S, van Beusekom HM, van der Giessen WJ (2006) Polymers, drug release, and drugeluting stents. J Interv Cardiol 19:500-506
22. Corporation BS (2007) TAXUS IV final 5-year outcomes, taken from Boston Scientific web site: www.bostonscientific.com, Boston Scientific Corporation
23. Creel CJ, Lovich MA, Edelman ER (2000) Arterial paclitaxel distribution and deposition. Circ Res 86:879-884
24. Daemen J, Ong AT, Stefanini GG, Tsuchida K, Spindler H, Sianos G, de Jaegere PP, van Domburg RT, Serruys PW (2006) Three-year clinical follow-up of the unrestricted use of sirolimuseluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Am J Cardiol 98:895-901
25. Daemen J, Serruys PW (2007) Drug-eluting stent update 2007: part I. A survey of current and future generation drug-eluting stents: meaningful advances or more of the same? Circulation 116:316-328
26. Dawkins K, Verheye S, Schühlen H, Dens J, Mudra H, Rutsch W, Stella P, Di Mario C, Thomas M, Serruys PW, Colombo A (2007) The European cobalt STent with antiproliferative for restenosis trial (EuroSTAR): 12 month results. Eur Heart J 3:82-88
27. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME (2005) Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 112:3306-3313
28. Duda SH, Poerner TC, Wiesinger B, Rundback JH, Tepe G, Wiskirchen J, Haase KK (2003) Drugeluting stents: potential applications for peripheral arterial occlusive disease. J Vasc Interv Radiol 14:291-301
29. Eisinger M, Lee JS, Hefton JM, Darzynkiewicz Z, Chiao JW, de Harven E (1979) Human epidermal cell cultures: growth and differentiation in the absence of differentiation in the absence of dermal components or medium supplements. Proc Natl Acad Sci USA 76:5340-5344
30. Elcin AE, Elcin YM (2006) Localized angiogenesis induced by human vascular endothelial growth factor-activated PLGA sponge. Tissue Eng 12:959-968
31. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A (1998) Vessel size and long-term outcome after coronary stent placement. Circulation 98:1875-1880
32. Elsner JJ, Zilberman M (2009) Antibiotic-eluting bioresorbable composite fibers for wound healing applications: microstructure, drug delivery and mechanical properties. Acta Biomater 5:2872-2883
33. Fajadet J,Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE (2006) Randomized, double-blind, multicenter study of the Endeavor zotarolimuseluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114:798-806
34. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R (1999) Pathology of acute and chronic coronary stenting in humans. Circulation 99:44-52
35. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R (2007) Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115:2435-2441
36. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shaknovish A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S (1994) A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med 331:496-501
37. Foye WO, Lemke TL, Williams DA (1998) Principles of medicinal chemistry, 3rd edn. Lea & Febiger, Baltimore, MD
38. Fraser JF, Bodman J, Sturgess R, Faoagali J, Kimble RM (2004) An in vitro study of the antimicrobial efficacy of a 1% silver sulphadiazine and 0.2% chlorhexidine digluconate cream, 1% silver sulphadiazine cream and a silver coated dressing. Burns 30:35-41
39. Freed M, Safian RD, Grines C (1996) Manual of interventional cardiology. Physicians' Press, Birmingham, MI
40. Gao RL, Xu B, Lu SZ, Chen JL, Han YL, Chen JZ, Gai LY, Ge JB, Wang WM, Du ZM, Huo Y, Wang LF, Gao W, Chen JY, He B, Jia GL, Yang ZJ, Cao KJ, Li WM, Shen WF, Wan Z, Huang DJ, Zhu GY (2008) Safety and efficacy of the CYPHER select sirolimus-eluting stent in the "Real World"-clinical and angiographic results from the China CYPHER select registry. Int J Cardiol 125:339-346
41. George J, Sack J, Barshack I, Keren P, Goldberg I, Haklai R, Elad-Sfadia G, Kloog Y, Keren G (2004) Inhibition of intimal thickening in the rat carotid artery injury model by a nontoxic Ras inhibitor. Arterioscler Thromb Vasc Biol 24:363-368
42. Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, Reifart N, Missault L, Goy JJ, Brinker JA, Raizner AE, Urban P, Heldman AW (2004) Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 109:487-493
43. Gershlick AH (2005) Drug eluting stents in 2005. Heart 91(Suppl 3):iii24-iii31
44. Gold HS, Moellering RC Jr (1996) Antimicrobial-drug resistance. N Engl J Med 335:1445-1453
45. Gransden WR (1997) Antibiotic resistance. Nosocomial gram-negative infection. J Med Microbiol 46:436-439
46. Grinberg O (2007) Highly porous bioresorbable scaffolds with controlled release of bioactive agents for tissue regeneration applications. MSc thesis. Tel Aviv University
47. Gristina AG (1987) Biomaterial-centered infection: microbial adhesion versus tissue integration. Science 237:1588-1595
48. Grube E (2008) Novel drug eluting stent system for customised treatment of coronary lesions: CUSTOM I feasibility trial 24 month results. Eur Heart J 4:71-76
49. Grube E, Bullesfeld L (2002) Initial experience with paclitaxel-coated stents. J Interv Cardiol 15:471-475
50. Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ (2004) Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 109:2168-2171
51. Halkin A, Stone GW (2004) Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials. J Interv Cardiol 17:271-282
52. Heggers J, Goodheart RE, Washington J, McCoy L, Carino E, Dang T, Edgar P, Maness C, Chinkes D (2005) Therapeutic efficacy of three silver dressings in an infected animal model. J Burn Care Rehabil 26:53-56
53. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, Nater C, Hruban RH, Rezai B, Abella BS, Bunge KE, Kinsella JL, Sollott SJ, Lakatta EG, Brinker JA, Hunter WL, Froehlich JP (2001) Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103:2289-2295
54. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, Ligthart JM, van Essen D, de Feyter PJ, Serruys PW (2006) Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 27:166-170
55. Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE (2004) Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109:634-640
56. Howard D, Buttery LD, Shakesheff KM, Roberts SJ (2008) Tissue engineering: strategies, stem cells and scaffolds. J Anat 213:66-72
57. Hutchinson FG, Furr BJ (1985) Biodegradable polymers for the sustained release of peptides. Biochem Soc Trans 13:520-523
58. Ignatova M, Starbova K, Markova N, Manolova N, Rashkov I (2006) Electrospun nano-fibre mats with antibacterial properties from quaternised chitosan and poly(vinyl alcohol). Carbohydr Res 341:2098-2107
59. Iofina E, Langenberg R, Blindt R, Kuhl H, Kelm M, Hoffmann R (2006) Polymer-based paclitaxel- eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions. Am J Cardiol 98:1022-1027
60. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193-202
61. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R (2008) Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 52:333-342
62. Jones SA, Bowler PG, Walker M, Parsons D (2004) Controlling wound bioburden with a novel silver-containing hydrofiber dressing. Wound Repair Regen 12:288-294
63. Jürgens C, Schulz AP, Porté T, Faschingbauer M, Seide K (2006) Biodegradable films in trauma and orthopedic surgery. Eur J Trauma 2:160-171
64. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ (1997) Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 30:1428-1436
65. Katti DS, Robinson KW, Ko FK, Laurencin CT (2004) Bioresorbable nanofiber-based systems for wound healing and drug delivery: optimization of fabrication parameters. J Biomed Mater Res B Appl Biomater 70:286-296
66. Kau U (2007) CObalt Chromium STent with antiproliferative for restenosis trial in India (COSTAR I). Indian Heart J 59:167-172
67. Kloog Y, Cox AD (2004) Prenyl-binding domains: potential targets for Ras inhibitors and anticancer drugs. Semin Cancer Biol 14:253-261
68. Knill CJ, Kennedy JF, Mistry J, Miraftab M, Smart G, Groocock MR, Williams HJ (2004) Alginate fibres modified with unhydrolysed and hydrolysed chitosans for wound dressings. Carbohydr Polym 55:65-76
69. Kraitzer A, Kloog Y, Zilberman M (2007) Approaches for prevention of restenosis. J Biomed Mater Res B Appl Biomater 85B:583-603
70. Kraitzer A, Kloog Y, Zilberman M (2009) Novel farnesylthiosalicylate (FTS)-eluting composite structures. Eur J Pharm Sci 37:351-362
71. Kraitzer A, Ofek L, Schreiber R, Zilberman M (2008) Long-term in vitro study of paclitaxeleluting bioresorbable core/shell fiber structures. J Control Release 126:139-148
72. Kraitzer A, Zilberman M (2007) Paclitaxel-loaded composite fibers: microstructure and emulsion stability. J Biomed Mater Res A 81:427-436
73. Kraitzer A, Zilberman M (2009) Novel Farnesylthiosalicylate (FTS) -Eluting Composite Structures. J Control Release 37(3-4):351-362
74. Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA 3rd, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB Jr, Schofer J, Buchbinder M, Wijns W (2008) A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol 51:1543-1552
75. Kutryk MJ (2003) Drug eluting stents for the treatment of coronary artery disease part 4: New results from clinical trials and future directions, Cardiology Rounds VIII, issue 10
76. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L (2007) Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356:1009-1019
77. Langer R, Vacanti JP (1993) Tissue engineering. Science 260:920-926
78. Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, O'Shaughnessy C, Applegate RA, Cannon LA, Mooney M, Farah A, Tannenbaum MA, Yakubov S, Kereiakes DJ, Wong SC, Kaplan B, Cristea E, Stone GW, Leon MB, Knopf WD, O'Neill WW (2004) Non-polymerbased paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 109:1948-1954
79. Lee SH, Szinai I, Carpenter K, Katsarava R, Jokhadze G, Chu CC, Huang Y, Verbeken E, Bramwell O, De Scheerder I, Hong MK (2002) In-vivo biocompatibility evaluation of stents coated with a new biodegradable elastomeric and functional polymer. Coron Artery Dis 13:237-241
80. Lewis AL, Tolhurst LA, Stratford PW (2002) Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. Biomaterials 23:1697-1706
81. Lincoff AM, et al (1997) Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 29:808-816
82. Liu X, Huang Y, Hanet C, Vandormael M, Legrand V, Dens J, Vandenbossche JL, Missault L, Vrints C, De Scheerder I (2003) Study of antirestenosis with the BiodivYsio dexamethasoneeluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv 60:172-178, discussion 179
83. Maruguchi T, Maruguchi Y, Suzuki S, Matsuda K, Toda K, Isshiki N (1994) A new skin equivalent: keratinocytes proliferated and differentiated on collagen sponge containing fibroblasts. Plast Reconstr Surg 93:537-544, Discussion 545-546
84. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356:1020-1029
85. Medsystems C (2007) Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent Trial Conclusions. Johnson & Johnson press release
86. Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Popma JJ, Cutlip DE, Fitzgerald PJ (2007a) Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. Am J Cardiol 100:56M-61M
87. Meredith IT, Worthley S, Whitbourn R, Walters D, Popma J, Cutlip D, Fitzgerald P (2007b) The next-generation EndeavorTM ResoluteTM stent: 4-month clinical and angiographic results from the ResoluteTM first-in-man trial. Euro Intervention 3:50-53
88. Mi FL, Wu YB, Shyu SS, Schoung JY, Huang YB, Tsai YH, Hao JY (2002) Control of wound infections using a bilayer chitosan wound dressing with sustainable antibiotic delivery. J Biomed Mater Res 59:438-449
89. Miyazawa A, Ako J, Hongo Y, Hur SH, Tsujino I, Courtney BK, Hassan AH, Kandzari DE, Honda Y, Fitzgerald PJ (2008) Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. Am Heart J 155:108-113
90. Moreno R, Macaya C (2005) Stent-based delivered anti-proliferative drugs in the prevention of coronary stent restenosis. Curr Med Chem Cardiovasc Hematol Agents 3:221-229
91. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP (2006) Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. J Am Med Assoc 295:895-904
92. Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, Snead D, Mauri L, Cutlip DE, Sousa E (2007) Long-term clinical outcomes with sirolimus-eluting coronary stents: fiveyear results of the RAVEL trial. J Am Coll Cardiol 50:1299-1304
93. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-1780
94. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323
95. Muzzarelli R, Tarsi R, Filippini O, Giovanetti E, Biagini G, Varaldo PE (1990) Antimicrobial properties of N-carboxybutyl chitosan. Antimicrob Agents Chemother 34:2019-2023
96. Nguyen KT, Su SH, Zilberman M, Bohluli P, Frenkel P, Tang L, Eberhart RC (2004) Biomaterials and stent technology. In: Yaszemski M, Rantolo D, Lewandrowski KU, Hasirci V, Altobelli D, Wise D (eds) Tissue engineering and novel delivery systems. Marcel Dekker, New York, pp 107-130
97. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S (2008) A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371:899-907
98. Ostojik M, Sagic D, Beleslin B, Jung R, Perisic Z, Jagic N, Nedeljkovic M, Mangovski L, Milosavljevic B, Stojkovic S, Orlic D, Antonic Z, Miloradovic V, Topic D, Paunovic D (2008) First clinical comparison of Nobori-Biolimus A9 eluting stents with Cypher-Sirolimus eluting stents: NOBORI CORE nine months angiographic and one year clinical outcomes. Euro Intervention 3:574-579
99. Park SN, Kim JK, Suh H (2004) Evaluation of antibiotic-loaded collagen-hyaluronic acid matrix as a skin substitute. Biomaterials 25:3689-3698
100. Peterson L (2004) PARIS COURSE ON REVASCULARIZATION (PCR) Trends-in-Medicine. Stephen Snyder, Paris, France
101. Planer D, Beyar R, Almagor Y, Banai S, Guetta V, Miller H, Kornowski R, Brandes S, Krakover R, Solomon M, Lotan C (2008) Long-term (>3 Years) outcome and predictors of clinical events after insertion of sirolimus-eluting stent in one or more native coronary arteries (from the Israeli arm of the e-Cypher registry). Am J Cardiol 101:953-959
102. Popma JJ (2007) Stent Design, Materials, Polymers and Drugs for DES
103. Prabu P, Dharmaraj N, Aryal S, Lee BM, Ramesh V, Kim HY (2006) Preparation and drug release activity of scaffolds containing collagen and poly(caprolactone). J Biomed Mater Res A 79:153-158
104. Price JS, Tencer AF, Arm DM, Bohach GA (1996) Controlled release of antibiotics from coated orthopedic implants. J Biomed Mater Res 30:281-286
105. Pruitt BA Jr, Levine NS (1984) Characteristics and uses of biologic dressings and skin substitutes. Arch Surg 119:312-322
106. Radu FA, Bause M, Knabner P, Lee GW, Friess WC (2002) Modeling of drug release from collagen matrices. J Pharm Sci 91:964-972
107. Rao SV, Califf RM, Kramer JM, Peterson ED, Gross TP, Pepine CJ, Williams DO, Donohoe D, Waksman R, Mehran R, Krucoff MW (2008) Postmarket evaluation of breakthrough technologies. Am Heart J 156:201-208
108. Rao SV, Shaw RE, Brindis RG, Klein LW, Weintraub WS, Peterson ED (2006) On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol 97:1478-1481
109. REVA Medical I (2007) REVA Medical Announces Enrollment of First Patients in the RESORB Clinical Trial
110. Revathi G, Puri J, Jain BK (1998) Bacteriology of burns. Burns 24:347-349
111. Ribichini F, Tomai F, Paloscia L, Di Sciascio G, Carosio G, Romano M, Verna E, Galli M, Tamburino C, De Cesare N, Pirisi R, Piscione F, Lanteri G, Ferrero V, Vassanelli C (2007) Steroid-eluting stents in patients with acute coronary syndrome: the dexamethasone eluting stent Italian registry. Heart 93:598-600
112. Roenigk RK, Roenigk HH (1989) Dermatologic surgery: principles and practice. M. Dekker, New York
113. Rogers CD (2004) Optimal stent design for drug delivery. Rev Cardiovasc Med 5(Suppl 2): S9-S15
114. Rossi S, Marciello M, Sandri G, Ferrari F, Bonferoni MC, Papetti A, Caramella C, Dacarro C, Grisoli P (2007) Wound dressings based on chitosans and hyaluronic acid for the release of chlorhexidine diacetate in skin ulcer therapy. Pharm Dev Technol 12:415-422
115. Roy P, Bonello L, de Labriolle A, Okabe T, Pinto Slottow TL, Steinberg DH, Torguson R, Smith K, Xue Z, Satler LF, Kent KM, Suddath WO, Pichard AD, Waksman R (2008) Twoyear outcome of patients treated with sirolimus- versus paclitaxel-eluting stents in an unselected population with coronary artery disease (from the REWARDS Registry). Am J Cardiol 102:292-297
116. Ruszczak Z, Friess W (2003) Collagen as a carrier for on-site delivery of antibacterial drugs. Adv Drug Deliv Rev 55:1679-1698
117. Saito Y, Minami K, Kobayashi M, Nakao Y, Omiya H, Imamura H, Sakaida N, Okamura A (2002) New tubular bioabsorbable knitted airway stent: biocompatibility and mechanical strength. J Thorac Cardiovasc Surg 123:161-167
118. Salam AM, Al Suwaidi J, Holmes DR Jr (2006) Drug-eluting coronary stents. Curr Probl Cardiol 31:8-119
119. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ (2004) The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 43:1110-1115
120. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G (2003) Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362:1093-1099
121. Serruys P (2005) Randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. Eur Heart J 1:58-65
122. Serruys P (2006) Randomized comparison of an everolimus eluting coronary stent with a paclitaxel eluting coronary stent: the SPIRIT II trial. Eur Heart J 2:286-294
123. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel MA (1994) A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 331:489-495
124. Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H, Smits P, McClean D, Verheye S, Belardi J, Condado J, Pieper M, Gambone L, Bressers M, Symons J, Sousa E, Litvack F (2005) The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 46:253-260
125. Shanmugasundaram N, Sundaraseelan J, Uma S, Selvaraj D, Babu M (2006) Design and delivery of silver sulfadiazine from alginate microspheres- impregnated collagen scaffold. J Biomed Mater Res B Appl Biomater 77:378-388
126. Sousa JE, Serruys PW, Costa MA (2003a) New frontiers in cardiology: drug-eluting stents: part I. Circulation 107:2274-2279
127. Sousa JE, Serruys PW, Costa MA (2003b) New frontiers in cardiology: drug-eluting stents: part II. Circulation 107:2383-2389
128. Springer BD, Lee GC, Osmon D, Haidukewych GJ, Hanssen AD, Jacofsky DJ (2004) Systemic safety of high-dose antibiotic-loaded cement spacers after resection of an infected total knee arthroplasty. Clin Orthop Relat Res 427:47-51
129. Sripriya R, Kumar MS, Sehgal PK (2004) Improved collagen bilayer dressing for the controlled release of drugs. J Biomed Mater Res B Appl Biomater 70:389-396
130. Stack RS, Califf RM, Phillips HR, Pryor DB, Quigley PJ, Bauman RP, Tcheng JE, Greenfield JC Jr (1988) Interventional cardiac catheterization at Duke Medical Center. Am J Cardiol 62:3F-24F
131. Stella PR et al (2008) One year results of a new in situ length-adjustable stent platform with a biodegradable biolimus A9 eluting polymer: results of the CUSTOM-II trial. Eur Heart J 4(2):200-207
132. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME (2004) One-year clinical results with the slowrelease, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109:1942-1947
133. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ (2008) Comparison of an everolimuseluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. J Am Med Assoc 299:1903-1913
134. Sussman C, Bates-Jensen BM (2001) Wound care: a collaborative practice manual for physical therapists and nurses, 2nd edn. Aspen Publishers, Gaithersburg, Md
135. Suzuki Y, Tanihara M, Nishimura Y, Suzuki K, Kakimaru Y, Shimizu Y (1997) A novel wound dressing with an antibiotic delivery system stimulated by microbial infection. Asaio J 43:M854-M857
136. Suzuki Y, Tanihara M, Nishimura Y, Suzuki K, Kakimaru Y, Shimizu Y (1998) A new drug delivery system with controlled release of antibiotic only in the presence of infection. J Biomed Mater Res 42:112-116
137. Taddeucci P, Pianigiani E, Colletta V, Torasso F, Andreassi L, Andreassi A (2004) An evaluation of Hyalofill-F plus compression bandaging in the treatment of chronic venous ulcers. J Wound Care 13:202-204
138. Tamai H, Igaki K, Tsuji T (1999) A biodegradable poly-L-lactic acid coronary stent in porcine coronary artery. J Intervent Cardiol 12:443-449
139. Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, Komori H, Tsuji T, Motohara S, Uehata H (2000) Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102:399-404
140. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, de Feyter P, Muller R, Regar E, Degertekin M, Ligthart JM, Disco C, Backx B, Russell ME (2003) TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 107:559-564
141. Tepe G, Wendel HP, Khorchidi S, Schmehl J, Wiskirchen J, Pusich B, Claussen CD, Duda SH (2002) Thrombogenicity of various endovascular stent types: an in vitro evaluation. J Vasc Interv Radiol 13:1029-1035
142. Trafny EA, Kowalska K, Grzybowski J (1998) Adhesion of Pseudomonas aeruginosa to collagen biomaterials: effect of amikacin and ciprofloxacin on the colonization and survival of the adherent organisms. J Biomed Mater Res 41:593-599
143. Trop M (2006) Silver-coated dressing acticoat caused raised liver enzymes and argyria-like symptoms in burn patient. J Trauma 61:1024
144. Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Pietras C, Shimada Y, Sonoda S, Cristea E, Negoita M, Dangas GD, Moses JW, Leon MB, Fitzgerald PJ, Muller R, Storger H, Hauptmann KE, Grube E (2006) Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol 98:464-469
145. Turco MA, Ormiston JA, Popma JJ, Mandinov L, O'Shaughnessy CD, Mann T, McGarry TF, Wu CJ, Chan C, Webster MW, Hall JJ, Mishkel GJ, Cannon LA, Baim DS, Koglin J (2007) Polymer-based, paclitaxel-eluting TAXUS Liberte stent in de novo lesions: the pivotal TAXUS ATLAS trial. J Am Coll Cardiol 49:1676-1683
146. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, Berge C, Deme M, Stoll HP (2006) Safety of coronary sirolimus-eluting stents in daily clinical practice: 1-year follow-up of the e-Cypher registry. Circulation 113:1434-1441
147. Uurto I et al (2005) Drug-eluting biodegradable poly-D/L-lactic acid vascular stents: an experimental pilot study. J Endovasc Ther 12(3):371-379
148. Varghese MC, Balin AK, Carter DM, Caldwell D (1986) Local environment of chronic wounds under synthetic dressings. Arch Dermatol 122:52-57
149. Venkatraman S, Boey F (2007) Release profiles in drug-eluting stents: issues and uncertainties. J Control Release 120:149-160
150. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109:701-705
151. Vogt F et al (2004) Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 25:1330-1340
152. Vranckx P, Serruys PW, Gambhir S, Eduardo SJ, Abizaid A, Lemos P, Ribeiro E, Dani SI, Dalal JJ, Mehan V, Dhar A, Dutta AL, Reddy KN, Chand R, Ray A (2006) Biodegradablepolymer- based, paclitaxel-eluting InfinniumTM stent: 9-month clinical and angiographic follow- up results from the SIMPLE II prospective multi-centre registry study. Euro Intervention 2:310-317
153. Waksman R (2006) Update on bioabsorbable stents: from bench to clinical. J Interv Cardiol 19:414-421
154. Wang X, Venkatraman SS, Boey FY, Loo JS, Tan LP (2006) Controlled release of sirolimus from a multilayered PLGA stent matrix. Biomaterials 27:5588-5595
155. Wei G, Jin Q, Giannobile WV, Ma PX (2006) Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB. J Control Release 112:103-110
156. Whang K, Thomas CH, Healy KE and Nuber G. (1995) A novel method to fabricate bioabsorbable scaffolds. Polymer 36:837-842
157. Whang K, Tsai DC, Nam EK, Aitken M, Sprague SM, Patel PK and Healy KE (1998) Ectopic bone formation via rhBMP-2 delivery from porous bioabsorbable polymer scaffolds. J Biomed Mat Res 42:491-499
158. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Juni P (2008) Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372:1163-1173
159. Woods TC, Marks AR (2004) Drug-eluting stents. Annu Rev Med 55:169-178
160. Wu P, Grainger DW (2006) Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials 27:2450-2467
161. Xu RX, Sun X, Weeks BS (2004) Burns regenerative medicine and therapy. Karger, Basel
162. Yamawaki T et al (1998) Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J Am Coll Cardiol 32:780-786
163. Ye YW et al (1998) Bioresorbable microporous stents deliver recombinant adenovirus gene transfer vectors to the arterial wall. Ann Biomed Eng 26:398-408
164. Zalavras CG, Patzakis MJ, Holtom P (2004) Local antibiotic therapy in the treatment of open fractures and osteomyelitis. Clin Orthop Relat Res 427:86-93
165. Zhu XH, Wang CH, Tong YW (2008) In vitro characterization of hepatocyte growth factor release from PHBV/PLGA microsphere scaffold. J Biomed Mater Res A 89(2):411-423
166. Zidar J, Lincoff A, Stack R (1999) Biodegradable stents. In: Topol EJ (ed) Textbook of interventional cardiology, 3rd edn. WB Saunders, Philadelphia, pp 787-802
167. Zilberman M, Golerkansky E, Elsner JJ, Berdicevsky I (2009) Gentamicin-eluting bioresorbable composite fibers for wound healing applications. J Biomed Mater Res A 89:654-666
168. Zilberman M, Schwade ND, Eberhart RC (2004) Protein-loaded bioresorbable fibers and expandable stents: mechanical properties and protein release. J Biomed Mater Res B Appl Biomater 69:1-10